Dušica Maysinger - Pharma

Author Information

Dusica Maysinger is a renowned researcher in the field of pharmacology, with a specific focus on the interactions between nanomaterials and biological systems. She is affiliated with the Department of Pharmacology and Therapeutics at McGill University in Montreal, Canada. Her work often explores the biocompatibility and effects of nanostructures in various cellular environments, contributing significantly to the advancement of nanomedicine.

Research Contributions

Dusica Maysinger has made substantial contributions to the understanding of nanoclusters and their interactions with proteins, as well as their impact on cellular systems. Her recent research includes studies on gold nanoclusters and their effects on human microglia and astrocytes, as well as the development of innovative nanomedicine approaches for treating ischemic stroke. Additionally, she has explored the synthesis and drug release mechanisms of miktoarm star polymers and has utilized mass spectrometry imaging to assess drug safety and metabolism in zebrafish larvae.

Aliases

Dusica Maysinger is also known by several aliases including D Maysinger, D. Maysinger, and Dušica Maysinger. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Total Citations	15,948
h-index	54
Total Papers	278

Publications:

Open questions on proteins interacting with nanoclusters

DOI: 10.1038/s42004-022-00665-9

Year: 2022

Insights into the Impact of Gold Nanoclusters Au10SG10 on Human Microglia.

DOI: 10.1021/acschemneuro.1c00621

Year: 2022

Miktoarm Star Polymers with Environment-Selective ROS/GSH Responsive Locations: From Modular Synthesis to Tuned Drug Release through Micellar Partial Corona Shedding and/or Core Disassembly.

DOI: 10.1002/mabi.202000305

Year: 2021

Size and ligand effects of gold nanoclusters in alteration of organellar state and translocation of transcription factors in human primary astrocytes.

DOI: 10.1039/d0nr06401g

Year: 2021

Insights into Interactions between Interleukin-6 and Dendritic Polyglycerols

DOI: 10.3390/ijms22052415

Year: 2021

New Approaches in Nanomedicine for Ischemic Stroke

DOI: 10.3390/pharmaceutics13050757

Year: 2021

Miktoarm Star Polymers with Environment‐Selective ROS/GSH Responsive Locations: From Modular Synthesis to Tuned Drug Release through Micellar Partial Corona Shedding and/or Core Disassembly

DOI: 10.1002/mabi.202170005

Year: 2021

Human astrocytes and astrocytoma respond differently to resveratrol.

DOI: 10.1016/j.nano.2021.102441

Year: 2021

Mass spectrometry imaging in zebrafish larvae for assessing drug safety and metabolism

DOI: 10.1007/s00216-021-03476-4

Year: 2021

Understanding the Interaction of Polyelectrolyte Architectures with Proteins and Biosystems

DOI: 10.1002/anie.202006457

Year: 2020

How Do Collaborative Care Models Work?

What are Collaborative Care Models?

What Are the Challenges in Managing Chronic Conditions?

What is Cellular Stress?

What Challenges Do Pharmacists Face?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

Why is Generic Competition Important?

What are the Challenges Faced by Generic Manufacturers?

What are the Phases of Clinical Trials?

How Can Technology Aid in Management?

Partnered Content Networks

Relevant Topics